Generic Name and Formulations:
Neisseria meningitidis polysaccharides 4mcg each of Group A, C, Y, and W-135; per 0.5mL; (diphtheria toxoid conjugate); soln for IM inj; preservative-free.

Company:
Sanofi Pasteur, Inc.
Indications for MENACTRA:
Meningitis immunization.

Adults and Children:
<9mos: not recommended. Give by IM inj only in deltoid region. Primary vaccination: 9–23mos: 0.5mL given as 2-dose series three months apart; 2–55yrs: 0.5mL once. Booster vaccination: 15–55yrs: may give a single (0.5mL) dose for those at continued risk, if at least 4yrs have elapsed since the prior dose.

Contraindications:
Severe allergic reaction to any previous meningococcal capsular polysaccharide-, diphtheria toxoid- or CRM197-containing vaccine.

Warnings/Precautions:
Have epinephrine inj (1:1000) available. History of Guillain-Barre syndrome. Immunosuppressed. Risk of syncope. Latex allergy. Adults >55yrs old. Pregnancy (Cat.C). Nursing mothers.

Interactions:
Immunosuppressants (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, high-dose steroids) may get suboptimal response. Concomitant vaccines: see full labeling.

Adverse Reactions:
Inj site reactions, headache, fatigue, malaise, arthralgia, vomiting, diarrhea, anorexia, chills, fever, rash, irritability, drowsiness; children: also, abnormal crying.

Note:
To register pregnant patients or to report adverse events call (800) 822-2463. Refer to www.cdc.gov for ACIP guidelines on vaccinating acutely ill patients.

How Supplied:
Single-dose vials—5